Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | FPR2 | P25090 | 4/20 | 0.60 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.57 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.57 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | CDK9 | P50750 | 1/20 | 0.57 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4118553 | 0.91 | NPC1 (0.69) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4112443 | 0.88 | NPC1 (0.71) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4112362 | 0.88 | NPC1 (0.67) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4112024 | 0.87 | NPC1 (0.63) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4115751 | 0.87 | NPC1 (0.67) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4112951 | 0.87 | NPC1 (0.61) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4117300 | 0.86 | NPC1 (0.67) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4105335 | 0.86 | NPC1 (0.64) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4115616 | 0.86 | NPC1 (0.65) | NPC1RAB9AKMT2AMAPTMEN1 | |
| SCHEMBL4548132 | 0.85 | IDH1 (0.64) | NPC1RAB9AKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228630-B1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-03-05 | — | — | EP | claimed |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-08-22 | — | — | US | claimed |
| EP-4228630-B1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-03-05 | — | — | EP | disclosed |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-08-22 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | NPC1 927/4885RAB9A 815/4885KMT2A 2807/4885 |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | NPC1 146/4885RAB9A 2409/4885KMT2A 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.